CSL (OTCMKTS:CSLLY) Reaches New 12-Month Low – What’s Next?

Shares of CSL Limited Sponsored ADR (OTCMKTS:CSLLY) reached a new 52-week low on Thursday . The company traded as low as $17.00 and last traded at $17.3150, with a volume of 901321 shares trading hands. The stock had previously closed at $17.73.

Analyst Ratings Changes

CSLLY has been the topic of a number of analyst reports. Royal Bank Of Canada cut CSL from a “moderate buy” rating to a “hold” rating in a research note on Wednesday, February 11th. Canaccord Genuity Group downgraded shares of CSL from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Zacks Research lowered shares of CSL from a “hold” rating to a “strong sell” rating in a research report on Monday, May 11th. Finally, Citigroup cut shares of CSL from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 11th. Three equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Reduce”.

CSL Stock Up 0.1%

The firm’s fifty day moving average is $22.04 and its 200 day moving average is $42.82. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.15 and a current ratio of 2.57.

About CSL

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.